Back

Comparison of IA-2 Bridge ELISA and Radiobinding Assays for Progression Risk Assessment in Early-Stage Type 1 Diabetes

2026-02-01 endocrinology Title + abstract only
View on medRxiv
Show abstract

Stratifying progression from early-stage type 1 diabetes to clinical disease is essential for optimally timing disease-modifying therapies. We previously developed a progression likelihood score (PLS) that includes quantitative IA-2 autoantibody (IA-2A) measurements. This study aligned IA-2A thresholds used for PLS calculation between the radiobinding assay (RBA) and a commercially available RSR IA-2A ELISA to support broader clinical application. Serum samples from 349 children with stage 1 typ...

Predicted journal destinations